Meridian Bioscience Inc. (VIVO): Price and Financial Metrics
VIVO Stock Summary
- Meridian Bioscience Inc's stock had its IPO on February 26, 1992, making it an older stock than 81.31% of US equities in our set.
- In terms of twelve month growth in earnings before interest and taxes, Meridian Bioscience Inc is reporting a growth rate of 234.77%; that's higher than 93.45% of US stocks.
- Revenue growth over the past 12 months for Meridian Bioscience Inc comes in at 51.89%, a number that bests 90.01% of the US stocks we're tracking.
- Stocks that are quantitatively similar to VIVO, based on their financial statements, market capitalization, and price volatility, are ULBI, CRTO, VERB, RWLK, and CTS.
- Visit VIVO's SEC page to see the company's official filings. To visit the company's web site, go to www.meridianbioscience.com.
VIVO Stock Price Chart Interactive Chart >
VIVO Price/Volume Stats
| Current price | $21.08 | 52-week high | $30.65 |
| Prev. close | $21.71 | 52-week low | $5.51 |
| Day low | $20.88 | Volume | 612,800 |
| Day high | $22.13 | Avg. volume | 767,424 |
| 50-day MA | $22.74 | Dividend yield | N/A |
| 200-day MA | $19.56 | Market Cap | 909.50M |
Meridian Bioscience Inc. (VIVO) Company Bio
Meridian Biosciences is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic test kits, purified reagents and related products and offers biopharmaceutical enabling technologies. The company was founded in 1976 and is based in Cincinnati, Ohio.
VIVO Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $21.08 | $15.12 | -30% |
Below please find a table outlining a discounted cash flow forecast for VIVO, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Meridian Bioscience Inc ranked in the 44th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. The most interesting components of our discounted cash flow analysis for Meridian Bioscience Inc ended up being:
- Interest coverage, a measure of earnings relative to interest payments, is 38.31 -- which is good for besting 88.85% of its peer stocks (US stocks in the Healthcare sector with positive cash flow).
- The business' balance sheet suggests that 7% of the company's capital is sourced from debt; this is greater than only 22.87% of the free cash flow producing stocks we're observing.
- VIVO's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 3%; for context, that number is higher than 38.87% of tickers in our DCF set.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -32% |
| 1% | -31% |
| 2% | -30% |
| 3% | -30% |
| 4% | -29% |
| 5% | -28% |
Want more companies with a valuation profile/forecast similar to that of Meridian Bioscience Inc? See NVS, AMGN, LMAT, ADUS, and ABC.
Latest VIVO News From Around the Web
Below are the latest news stories about Meridian Bioscience Inc that investors may wish to consider to help them evaluate VIVO as an investment opportunity.
Meridian Bioscience corrects prior update on Revogene sars-cov-2 EUA withdrawalMeridian Bioscience ([[VIVO]] -8.0%) updates its communication regarding the withdrawal of its application for Emergency Use Authorization ((EUA)) with the U.S. FDA for the SARS-CoV-2 molecular diagnostic test on its Revogene platform.The FDA has now clarified that Meridian will not be able to distribute its SARS-CoV-2 molecular diagnostic test on its Revogene platform... |
SHAREHOLDER ALERT: Meridian Bioscience, Inc. Investigated for Possible Securities Laws Violations by Block & Leviton LLP; Investors Should Contact the FirmBOSTON, MA / ACCESSWIRE / February 23, 2021 / Block & Leviton LLP (www.com), a national securities litigation firm, announces that it is investigating Meridian Bioscience, Inc. |
Meridian Bioscience issues correction: It can't ship its Revogene SARS-CoV-2 test until EUA is grantedMeridian Bioscience Inc. issued a statement Tuesday afternoon, to correct a statement made earlier regarding its SARS-CoV-2 molecular diagnostic test on its Revogene platform. The stock dropped 8.7%, and has now tumbled 30.0% since it closed on Feb. 11 at the highest price since October 2008. After speaking with the Food and Drug Administration mid-morning Tuesday, the company said it will not be able to distribute its Revogene SARS-CoV-2 test until the test receives Emergency Use Authorization approval from the FDA. Earlier Tuesday, the company had said it would resume shipping of the tests once it notifies the FDA of its intent to re-submit an EUA application. The company said Tuesday that it had decided to withdraw its EUA application following further discussions with the FDA, which... |
Meridian Bioscience Corrects Prior Update Regarding Revogene® SARS-CoV-2 EUA WithdrawalCINCINNATI, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, updated its communication regarding the withdrawal of its application for Emergency Use Authorization (EUA) with the U.S. Food and Drug Administration (FDA) for the SARS-CoV-2 molecular diagnostic test on its Revogene® platform. In subsequent communication with the FDA mid-morning on February 23, 2021, the FDA clarified that Meridian will not be able to distribute its SARS-CoV-2 molecular diagnostic test on its Revogene® platform until the test receives EUA approval from the FDA. This corrects the Company’s prior statement that the Company would resume shipping the Revogene® SARS-CoV-2 test to customers upon notification of it... |
Meridian Bioscience Provides a Further Update on the Revogene® SARS-CoV-2 EUA SubmissionCINCINNATI, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, provided a further update on its application for Emergency Use Authorization (EUA) with the U.S. Food and Drug Administration (FDA) for the SARS-CoV-2 molecular diagnostic test on its Revogene® platform. Following the submission of Meridian’s written response to the FDA’s request for additional information on its Revogene® SARS-CoV-2 test on February 16, 2021 and further discussions with the FDA, on February 22, 2021, Meridian Bioscience elected to withdraw its EUA application. Between now and the end of March 2021 and based on guidance from the FDA, Meridian intends to conduct a new clinical validation study and a Limit-of-De... |
VIVO Price Returns
| 1-mo | -4.62% |
| 3-mo | 11.53% |
| 6-mo | 53.09% |
| 1-year | 163.83% |
| 3-year | 57.64% |
| 5-year | 14.06% |
| YTD | 12.79% |
| 2020 | 91.30% |
| 2019 | -43.29% |
| 2018 | 28.02% |
| 2017 | -18.02% |
| 2016 | -9.91% |
Continue Researching VIVO
Want to see what other sources are saying about Meridian Bioscience Inc's financials and stock price? Try the links below:Meridian Bioscience Inc (VIVO) Stock Price | Nasdaq
Meridian Bioscience Inc (VIVO) Stock Quote, History and News - Yahoo Finance
Meridian Bioscience Inc (VIVO) Stock Price and Basic Information | MarketWatch
Get Free Updates
Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!
Loading social stream, please wait...